Taiwan · Delayed Price · Currency is TWD OK Biotech Statistics
Total Valuation
OK Biotech has a market cap or net worth of TWD 1.88 billion. The enterprise value is 2.63 billion.
| Market Cap | 1.88B |
| Enterprise Value | 2.63B |
Important Dates
The next estimated earnings date is Thursday, April 2, 2026.
| Earnings Date | Apr 2, 2026 |
| Ex-Dividend Date | Jul 4, 2025 |
Share Statistics
OK Biotech has 141.12 million shares outstanding. The number of shares has decreased by -1.20% in one year.
| Current Share Class | 141.12M |
| Shares Outstanding | 141.12M |
| Shares Change (YoY) | -1.20% |
| Shares Change (QoQ) | +3.13% |
| Owned by Insiders (%) | 4.71% |
| Owned by Institutions (%) | 0.34% |
| Float | 101.70M |
Valuation Ratios
The trailing PE ratio is 23.44.
| PE Ratio | 23.44 |
| Forward PE | n/a |
| PS Ratio | 1.21 |
| PB Ratio | 0.73 |
| P/TBV Ratio | 0.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 5.91 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.09, with an EV/FCF ratio of -29.17.
| EV / Earnings | 31.94 |
| EV / Sales | 1.69 |
| EV / EBITDA | 13.09 |
| EV / EBIT | 24.27 |
| EV / FCF | -29.17 |
Financial Position
The company has a current ratio of 2.28, with a Debt / Equity ratio of 0.39.
| Current Ratio | 2.28 |
| Quick Ratio | 1.35 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | 5.05 |
| Debt / FCF | -11.22 |
| Interest Coverage | 9.88 |
Financial Efficiency
Return on equity (ROE) is 3.78% and return on invested capital (ROIC) is 3.08%.
| Return on Equity (ROE) | 3.78% |
| Return on Assets (ROA) | 1.79% |
| Return on Invested Capital (ROIC) | 3.08% |
| Return on Capital Employed (ROCE) | 3.27% |
| Weighted Average Cost of Capital (WACC) | 3.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.41 |
| Inventory Turnover | 2.28 |
Taxes
In the past 12 months, OK Biotech has paid 6.74 million in taxes.
| Income Tax | 6.74M |
| Effective Tax Rate | 6.49% |
Stock Price Statistics
The stock price has decreased by -33.75% in the last 52 weeks. The beta is 0.15, so OK Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | -33.75% |
| 50-Day Moving Average | 14.18 |
| 200-Day Moving Average | 15.16 |
| Relative Strength Index (RSI) | 36.76 |
| Average Volume (20 Days) | 241,605 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OK Biotech had revenue of TWD 1.56 billion and earned 82.45 million in profits. Earnings per share was 0.57.
| Revenue | 1.56B |
| Gross Profit | 429.25M |
| Operating Income | 107.89M |
| Pretax Income | 103.87M |
| Net Income | 82.45M |
| EBITDA | 187.37M |
| EBIT | 107.89M |
| Earnings Per Share (EPS) | 0.57 |
Balance Sheet
The company has 327.06 million in cash and 1.01 billion in debt, with a net cash position of -686.09 million or -4.86 per share.
| Cash & Cash Equivalents | 327.06M |
| Total Debt | 1.01B |
| Net Cash | -686.09M |
| Net Cash Per Share | -4.86 |
| Equity (Book Value) | 2.58B |
| Book Value Per Share | 17.81 |
| Working Capital | 701.65M |
Cash Flow
In the last 12 months, operating cash flow was 318.86 million and capital expenditures -409.14 million, giving a free cash flow of -90.28 million.
| Operating Cash Flow | 318.86M |
| Capital Expenditures | -409.14M |
| Depreciation & Amortization | 93.61M |
| Net Borrowing | 215.52M |
| Free Cash Flow | -90.28M |
| FCF Per Share | -0.64 |
Margins
Gross margin is 27.58%, with operating and profit margins of 6.93% and 5.30%.
| Gross Margin | 27.58% |
| Operating Margin | 6.93% |
| Pretax Margin | 6.67% |
| Profit Margin | 5.30% |
| EBITDA Margin | 12.04% |
| EBIT Margin | 6.93% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 2.25%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 2.25% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 53.11% |
| Buyback Yield | 1.20% |
| Shareholder Yield | 3.45% |
| Earnings Yield | 4.38% |
| FCF Yield | -4.79% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 6, 2023. It was a forward split with a ratio of 1.10213412.
| Last Split Date | Sep 6, 2023 |
| Split Type | Forward |
| Split Ratio | 1.10213412 |
Scores
OK Biotech has an Altman Z-Score of 1.96 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.96 |
| Piotroski F-Score | 6 |